Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
August 05, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
July 25, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Completes Licensing Agreement with 3SBio
July 24, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
July 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
June 26, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2025 Dividend
June 25, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
June 25, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 02, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
May 30, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
May 19, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
April 29, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
April 26, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Second-Quarter 2025 Dividend
April 23, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
April 23, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 16, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
April 14, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
April 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 01, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
March 18, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 24, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
January 28, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 25, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
January 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 06, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
